Long-term follow-up after rituximab plus bendamustine in a patient with relapsed or refractory hairy cell leukemia variant

摘要

Hairy cellleukemia variant (HCL-v) isarare B-cellchroniclymphoproliferative disorder regarded asasplenic B-celllymphoma/leukemia, unclassifiabletumor in the 2017 World HealthOrganization classification; it is nowconsidered to be distinct fromclassical hairy cellleukemia (HCL-c). Most patients withHCL-v exhibit poor responses or resistanceto standard treatments for HCL-c. [1] To the best of our knowledge, there have been fewreports regarding theeffect ofcombined chemotherapy for HCL-v,exceptaregimen involving rituximab and cladribine (Cd).